New Advances for NAFLDNASH NAFLD A Spectrum of Disease Who Is at Risk for NAFLD and NASH Prevalence of NAFLD in Europe Prevalence of NAFLD and NASH Predicted to Increase in Europe What Is the Burden of NAFLD in Europe ID: 773293
Download Presentation The PPT/PDF document "New Advances for NAFLD/NASH" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
New Advances for NAFLD/NASH
NAFLD: A Spectrum of Disease
Who Is at Risk for NAFLD and NASH?
Prevalence of NAFLD in Europe
Prevalence of NAFLD and NASH Predicted to Increase in Europe
What Is the Burden of NAFLD in Europe?
Economic and Health Burden of NASH in 5 European Countries: France, Germany, Italy, Spain and UK
Obesity, Metabolic Syndrome, and Alcohol Use: A Triple Threat?
NAFLD and HCC
NAFLD and HCC (cont)
Liver Transplantation for NASH in Europe
Should Patients With NAFLD Be Screened for HCC?
Current Burden of NAFLD-Related Disease Extrahepatic Greater Than Hepatic
NAFLD and Metabolic Syndrome: A Two-Way Street
The NAFLD/NASH Phenotype
Clinical Management Challenges
Identification of Patients at Risk
Risk Stratification of High-Risk Patients
Serum-Based Single Tests for Identifying Patients With NAFLD at Increased Risk for Worse Outcomes
The Camden and Islington NAFLD Pathway
Does Every Patient With Suspected NASH Need a Liver Biopsy?
Does Every Patient With Suspected NASH Need a Liver Biopsy? (cont)
What Does the Liver Biopsy Tell You and Is It Helpful to the Patient?
Treatment and Management Strategies for Improving Cardiovascular Risk
The Proportion of Weight Loss Matters
Are Statins Safe in Patients With NAFLD?
Pharmacologic Treatment of NAFLD and NASH
Current Ongoing Phase 3 Trials for NASH
REGENERATE: Ongoing Phase 3, Double-Blind, PBO-Controlled Study: 18-Month Secondary Analysis
Concluding Remarks
Abbreviations
Abbreviations (cont)
Abbreviations (cont)